RxDoctor Payments Data

Mario Ernesto Henriquez Alvarenga, MD

Family Medicine · Albuquerque, NMNPI 1972941813

Payments from drug & device makers

$310in general payments, 2019–2025

Across 20 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$67
  • Merck$43
  • AstraZeneca$39
  • Novo Nordisk$39
  • Pfizer$33
  • GSK$30
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$29896%
  • Education$124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$310 in reported general payments places this provider in the 65th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$23,980
Medicare patients
103
Services billed
308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$106,913
EliquisApixaban75$48,480
MounjaroTirzepatide31$38,218
TrulicityDulaglutide37$37,776
XareltoRivaroxaban37$31,768
FarxigaDapagliflozin Propanediol29$27,621
JardianceEmpagliflozin20$26,189
Gabapentin677$9,891
EntrestoSacubitril/Valsartan12$8,033
LinzessLinaclotide11$7,657
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$7,546
SymbicortBudesonide/Formoterol Fumarate32$7,501
Spiriva RespimatTiotropium Bromide14$7,201
Levothyroxine Sodium591$7,080
Lisinopril484$6,901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$39$106,913104 claims
Lilly USA, LLCMounjaro, Trulicity$67$75,99468 claims
PfizerEliquis$33$48,48075 claims
AstraZenecaFarxiga, Symbicort$39$35,12361 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →